Aspira Women’s Health Expands Lab to Advance ENDOinform Test

Austin, Texas, USA – April 23, 2026

Aspira Women’s Health announced a major operational milestone with the expansion of its molecular laboratory infrastructure, aimed at accelerating the development and commercialization of its ENDOinform™ noninvasive blood test for endometriosis. This strategic expansion supports clinical validation, assay performance optimization, and scalable deployment, positioning the company to address a significant unmet need in women’s health diagnostics through AI-powered multiomic technology.

Molecular Lab Expansion Drives Diagnostic Innovation

The completion of Aspira’s molecular laboratory buildout in Q2 2026 represents a critical step toward scaling its next-generation diagnostic platform. The enhanced facility enables high-throughput testing, improved reproducibility, and efficient assay development, which are essential for advancing ENDOinform™ toward clinical validation and commercialization readiness.

ENDOinform™ is designed as a first-of-its-kind multiomic blood test, integrating serum protein biomarkers, microRNA signatures, and clinical data to deliver accurate, early detection of endometriosis. This approach leverages artificial intelligence and computational analytics to improve diagnostic precision, potentially reducing reliance on invasive procedures such as laparoscopy, which are currently the standard for diagnosis.

By strengthening its laboratory capabilities, Aspira aims to accelerate development timelines and enhance data generation, ensuring that the test meets clinical performance and regulatory expectations.

Addressing Unmet Need in Endometriosis Diagnosis

Endometriosis is a chronic and often debilitating condition affecting more than 6.5 million women in the United States, frequently associated with pelvic pain, infertility, and reduced quality of life. Despite its prevalence, diagnosis is often delayed by several years due to the lack of reliable noninvasive diagnostic tools.

Aspira’s ENDOinform™ aims to transform this landscape by providing a noninvasive, blood-based diagnostic solution capable of earlier detection and improved patient stratification. The company’s clinical program includes analysis of over 400 prospectively collected patient samples and enrollment of more than 1,000 patients in ongoing studies, supporting robust validation of the test’s clinical utility.

This data-driven approach is expected to enhance confidence in diagnostic accuracy and support regulatory pathways, ultimately enabling broader adoption in clinical practice.

AI-Driven Multiomic Platform Enables Scalable Growth

Aspira’s strategy combines biomarker science, artificial intelligence, and scalable laboratory infrastructure to develop precision diagnostics for gynecologic diseases. The transition to a clinical digital PCR platform further enhances the test’s scalability, reproducibility, and operational efficiency, ensuring readiness for large-scale deployment in healthcare settings.

The expansion also aligns with growing demand for precision medicine solutions in women’s health, particularly as new therapies for endometriosis emerge. By enabling earlier diagnosis and better patient selection, ENDOinform™ could play a crucial role in improving treatment outcomes and reducing healthcare burden.

As the global diagnostics market continues to evolve, Aspira’s integrated approach positions it at the forefront of AI-enabled clinical decision support and multiomic innovation, offering a pathway to transform disease management through noninvasive, data-driven diagnostics.

Source: Aspira Women’s Health press release